HER2 status in unusual histological variants of gastric adenocarcinomas

Abstract

Trastuzumab has been confirmed as an additional useful therapeutic standard option for patients with HER2-positive advanced gastric cancers, and also in aggressive variants of adenocarcinomas such as HAS.

Impact of HER2 expression on outcome in gastric cancer patients with liver metastasis

“…According to previous studies, HER2-positivity rate was about 9-38 % [14][15][16][17][18][19]. In our current study, the overall HER2-positivity rate was 21 % in advanced and metastatic gastric cancer.…”

Hepatoid adenocarcinoma of the stomach: A case report and literature review

“…Levels of AFP in the serum and tumor tissue are significantly high in this form of gastric cancer; however, HAC is rare, accounting for 1.3-15% of gastric cancers (9). Although there have been some previous reports about this disease (10,11), there remains a lack of understanding. HAC is discussed here with reference to the present case and published literature.…”

Variants of Gastric Carcinoma: Morphologic and Theranostic Importance

“…Although reported rates of HER2 overexpres- Recently, Giuffre et al reported that a markedly increased HER2 amplification was more frequent in HACS (42.9%) than that seen in tubular gastric adenocarcinomas (31.3%) [1]. This finding shows trastuzumab can be a useful therapeutic standard option not only for patients with advanced gastric cancer but also in aggressive variants like HACS.…”